drugset / Trial / NCT04116047
CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)
Phase 3
Active not recruiting
785 enrolled
University of Birmingham
AstraZeneca · collabCancer Trials Ireland · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.
Timeline
- Start
- 2015-07
- Primary completion
- 2026-12
- Completion
- 2030-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |
| Background | Cisplatin | Other / unclassified | 40 mg/m2 | — |
| Background | Cisplatin | Other / unclassified | 100 mg/m2 | — |